Insulin resistance quantified by the value of HOMA‑IR and cardiovascular risk in patients with type 2 diabetes

Vladu,Ionela Mihaela; Forțofoiu,Maria; Clenciu,Diana; Forțofoiu,Mircea-Cătălin; Pădureanu,Rodica; Radu,Lucrețiu; Cojan,Ștefăniță Tiberiu Țenea; Rădulescu,Patricia Mihaela; Pădureanu,Vlad

doi:10.3892/etm.2021.10996

Insulin resistance quantified by the value of HOMA‑IR and cardiovascular risk in patients with type 2 diabetes

Authors:
- Ionela Mihaela Vladu
- Maria Forțofoiu
- Diana Clenciu
- Mircea-Cătălin Forțofoiu
- Rodica Pădureanu
- Lucrețiu Radu
- Ștefăniță Tiberiu Țenea Cojan
- Patricia Mihaela Rădulescu
- Vlad Pădureanu
View Affiliations

Affiliations: Department of Diabetes, Nutrition and Metabolic Diseases, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania, Department of Emergency, Emergency Clinical County Hospital of Craiova, 200349 Craiova, Romania, Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania, Department of Internal Medicine, Emergency Clinical County Hospital of Craiova, 200642 Craiova, Romania, Department of Hygiene, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania, Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania, Department of Pneumology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
Published online on: November 24, 2021 https://doi.org/10.3892/etm.2021.10996
Article Number: 73
Copyright: © Vladu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cardiovascular disease (CVD) is recognized as a leading cause of death worldwide. Obesity, dyslipidemia, insulin resistance (IR), interconnected pathological conditions constitute risk factors that are closely associated with CVD. The aim of the present study was to highlight the association of IR with cardiovascular risk (CVR). The epidemiological, cross‑sectional, non‑interventional study was conducted over 12 months (2019‑2020) within a research grant and included a sample of 400 subjects divided into 2 subgroups: group 1 (control) subjects did not have diabetes (n=200) and group 2 had type 2 diabetes (T2DM) (n=200). The Framingham risk score (FRS) was calculated according to the 2008 general CVD risk model from the Framingham Heart Study. Subsequent to a correlation of the value of homeostasis model assessment of insulin resistance (HOMA‑IR) with the degree of CVR, the IR was higher in both groups, and CVR also increased. After being quantified by the Spearman correlation coefficient, the correlation in group 2 was higher at 0.625 compared to group 1 where this coefficient had a value of 0.440. A high FRS (FRS of 20%) was significantly associated with IR. The results therefore show that HOMA‑IR is an independent risk factor for high FRS. New therapies focused on decreasing IR may contribute to decreased CVD.

View Figures

View References

1	Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A and Carmena R: Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 26:3320–3325. 2003.PubMed/NCBI View Article : Google Scholar
2	Grigorescu ED, Lăcătușu CM, Crețu I, Floria M, Onofriescu A, Ceasovschih A, Mihai BM and Șorodoc L: Self-reported satisfaction to treatment, quality of life and general health of type 2 diabetes patients with inadequate glycemic control from north-eastern Romania. Int J Environ Res Public Health. 18(3249)2021.PubMed/NCBI View Article : Google Scholar
3	Van Gaal LF, Mertens IL and De Block CE: Mechanisms linking obesity with cardiovascular disease. Nature. 444:875–880. 2006.PubMed/NCBI View Article : Google Scholar
4	Adiels M, Olofsson SO, Taskinen MR and Borén J: Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 28:1225–1236. 2008.PubMed/NCBI View Article : Google Scholar
5	Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA and Kahn CR: Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 6:87–97. 2000.PubMed/NCBI
6	Borén J, Taskinen M-R, Olofsson S-O and Levin M: Ectopic lipid storage and insulin resistance: A harmful relationship. J Intern Med. 274:25–40. 2013.PubMed/NCBI View Article : Google Scholar
7	Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest. 106:453–458. 2000.PubMed/NCBI View Article : Google Scholar
8	Reaven GM: Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab. 88:2399–2403. 2003.PubMed/NCBI View Article : Google Scholar
9	Ashcroft FM and Rorsman P: Diabetes mellitus and the β cell: The last ten years. Cell. 148:1160–1171. 2012.PubMed/NCBI View Article : Google Scholar
10	DeFronzo RA and Tripathy D: Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 32 (Suppl):S157–S163. 2009.PubMed/NCBI View Article : Google Scholar
11	Ferrannini E and Cushman WC: Diabetes and hypertension: The bad companions. Hypertension. 380:601–610. 2012.PubMed/NCBI View Article : Google Scholar
12	Steinberg HO, Brechtel G, Johnson A, Fineberg N and Baron AD: Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest. 94:1172–1179. 1994.PubMed/NCBI View Article : Google Scholar
13	Clenciu D, TeneaCojan TS, Dijmarescu A, Ene CG, Davitoiu DV, Baleanu VD, Ciora CA, Socea B, Voiculescu D, NedelcuŢă RM, et al: Diabetic retinopathy in relation with eGDR value in patients with type 1 diabetes mellitus. Rev Chim (Bucharest). 70:1434–1438. 2019.
14	Laakso M: Heart in diabetes: A microvascular disease. Diabetes Care. 34 (Suppl):S145–S149. 2011.PubMed/NCBI View Article : Google Scholar
15	The International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 32:1327–1334. 2009.PubMed/NCBI View Article : Google Scholar
16	Socea B, Radu L, Clenciu D, TeneaCojan TS, Baleanu VD, Ene CG, Girgavu SR and Vladu IM: The utility of visceral adiposity index in prediction of metabolic syndrome and hypercholesterolemia. RevChim (Bucharest). 69:3112–3114. 2018.
17	Vladu IM, Radu L, Girgavu SR, Baleanu V, Clenciu D, Ene CG, Socea B, Mazen E, Cristea OM, Mota M, et al: An easy way to detect cardiovascular risk. Rev Chim (Bucharest). 69:3229–3232. 2018.
18	American Diabetes Association: 2. Classification and diagnosis of diabetes. Standards of medical care in diabetes-2021. Diabetes Care. 44 (Suppl):S15–S33. 2021.
19	Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:412–419. 1985.PubMed/NCBI View Article : Google Scholar
20	D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro J and Kannel WB: General cardiovascular risk profile for use in primary care: The Framingham heart study. Circulation. 117:743–753. 2008.PubMed/NCBI View Article : Google Scholar
21	Hernandez-Rodas MC, Valenzuela R and Videla LA: Relevant aspects of nutritional and dietary interventions in non-alcoholic fatty liver disease. Int J Mol Sci. 16:25168–25198. 2015.PubMed/NCBI View Article : Google Scholar
22	Forțofoiu MC, Popescu DM, Pădureanu V, Dobrinescu AC, Dobrinescu AG, Mită A, Foarfă MC, Bălă VS, Muşetescu AE, Ionovici N and ForŢofoiu M: Difficulty in positive diagnosis of ascites and in differential diagnosis of a pulmonary tumor. Rom J Morphol Embryol. 58:1057–1064. 2017.PubMed/NCBI
23	Valenzuela R and Videla LA: The importance of the long-chain polyunsaturated fatty acid n-6/n-3 ratio in development of non-alcoholic fatty liver associated with obesity. Food Funct. 2:644–648. 2011.PubMed/NCBI View Article : Google Scholar
24	Grigorescu ED, Sorodoc V, Floria M, Anisie E, Popa AD, Onofriescu A, Ceasovschih A and Sorodoc L: The inflammatory marker hsCRP as a predictor of increased insulin resistance in type 2 diabetics without atherosclerotic manifestations. Rev Chim (Bucharest). 70:1791–1794. 2019.
25	Forţofoiu M, Forţofoiu MC, Comănescu V, Dobrinescu AC, Pădureanu V, Vere CC, Streba CT and Ciurea PL: Hepatocellular carcinoma and metabolic diseases-histological perspectives from a series of 14 cases. Rom J Morphol Embryol. 56:1461–1465. 2015.PubMed/NCBI
26	Mihailovici AR, Padureanu V, Albu CV, Dinescu VC, Pirlog MC, Dinescu SN, Malin RD and Calborean V: Myocardial Noncompaction. Rev Chim (Bucharest). 69:2209–2212. 2018.
27	Vladu M, Clenciu D, Efrem IC, Forţofoiu MC, Amzolini A, Micu ST, Mota M and Fortofoiu M: Insulin resistance and chronic kidney disease in patients with type 1 diabetes mellitus. J Nutr Metab. 2017(6425359)2017.PubMed/NCBI View Article : Google Scholar